Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown even greater efficacy in some studies, with weight reductions of approximately 20% in the SURMOUNT-1 trial
This is not a minor hack
The weight started dropping off almost immediately
Based on current trial progress and typical regulatory patterns, Canadians can reasonably expect Retatrutide approval sometime between late 2027 and mid 2028
US$ 20.18
US$ 26.86
US$ 23.36
US$ 20.06
US$ 29.75
